1 / 62

Antiphospholipid Syndrome

Antiphospholipid Syndrome. Prof. Dr. Suchitra N. Pandit MD, DNBE, DFP, FRCOG, FICOG, B.Pharm Consultant Obstetrician & Gynaecologist Kokilaben Dhirubhai Hospital, Mumbai ,India Clinical secretary –MOGS, Vice President - FOGSI (2008-09)

brit
Download Presentation

Antiphospholipid Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Antiphospholipid Syndrome

  2. Prof. Dr. Suchitra N. Pandit MD, DNBE, DFP, FRCOG, FICOG, B.Pharm Consultant Obstetrician & Gynaecologist Kokilaben Dhirubhai Hospital, Mumbai ,India Clinical secretary –MOGS, Vice President - FOGSI (2008-09) Chairperson -Young Talent promotion committee FOGSI (2003-07)

  3. Antiphospholipid ( APLA ) syndrome • Antiphospholipid syndrome (Hughes syndrome) is a disorder of immune system ,characterised by excessive clotting of blood ,thrombocytopenia & /or adverse pregnancy outcomes • Body recognizes negatively charged phospholipids on cell membrane as foreign & produces antibodies against them leading to an acquired autoimmune thrombophilia • Patients have laboratory evidence for antibodies ( IgG, IgM or IgA ) against phospholipids or phospholipid-binding protein cofactors in their blood

  4. How many types of APLA syndromes are there • A.) One • B.) two • C.) Three • D.) Four

  5. Antiphospholipid antibody syndrome (APLA) • Primary antiphospholipid syndrome (PAPS) - when APS occurs in the absence of any other related disease (LA, ACL antibodies in patient’s serum). • Secondary antiphospholipid syndrome - when APS coexists with other diseases such as SLE I • In catastrophic APLA (rare ), APS leads to rapid organ failure due to generalised thrombosis & a high risk of death • Other rare antibodies to phosphotidyl ethanolamine & phosphotidylserine are also associated with it

  6. Thrombophilic defects either acquired or inherited

  7. Thrombophilia - tendency to thrombosis Lupus anticoagulant antibodies Acquired APLA Anticardiolipin antibodies • Myeloprolipherative diseases • Malignancy • Paroxysmal nocturnal Haemoglobinuria • Nephrotic syndrome

  8. Inherited • Hyperhomocysteinemia (C677T) mutation • Factor V Leiden mutation (A506G) mutation • Mutation in prothrombin ( G 20210 A) • Prothrombin II (PTII) mutation • Protein S deficiency • Protein C deficiency

  9. All these conditions should be investigated for APLA except : A.) Early onset severe preeclampsia B.) Arterial or venous thrombosis C.) Unexplained fetal growth restriction D.) Gestational Diabetes

  10. Primary antiphospholipid antibody syndrome Presentation may be totally asymptomatic or in a classical manner : Various clinical presentations : • Recurrent pregnancy loss • Unexplained second or third trimester loss • Early onset severe preeclampsia • Arterial or venous thrombosis • Unexplained fetal growth restriction • Prolonged coagulation studies • Autoimmune diseases • Cardiac valvular diseases • Neurological disorders • Thrombocytopenia

  11. Diagnosis of APLA Challenging !!! • Due to fluctuating titers of the antibodies, • Lack of agreement between laboratories concerning standardization of the assays • Debates among researchers & clinicians concerning which antibodies to measure.

  12. Which is not an APLA antibody ? A.) Anti Ro B.) Lupus Anticoagulant (LAC) C.) Anticardiolipin Antibodies (ACL) D.) Anti insulin antibodies

  13. Which are the Antibodies • Lupus Anticoagulant (LAC) • Anticardiolipin Antibodies (ACL) • Anti Beta 2 glycoprotein antibodies • Other antibodies

  14. Lupus anticoagulant ( LAC) • LAC is characterized by a prolonged partial thromboplastin time & paradoxically the so-called ‘anticoagulant’ is a powerful thrombotic agent in vivo • Higher thrombotic potential than ACL when present alone • LAC interferes with platelet function, causing aggregation & thrombosis & also interferes with endothelial function, causing procoagulant activation & thrombosis • Prevalence of LAC in low risk population is < 1% Bad obstetric history - 9.1% Early pre eclampsia - 16%, Abruption - 33% Systemic lupus erythematosus - 34%

  15. Patient typically has a prolonged APTT that does not correct in 80:20 mixture with normal human plasma • Prolonged Dilute Russel viper venom time (DRVVT), Kaolin clotting test (KCT),(TDT/DTT) or prothombin time • Due to heterogeneous nature of LA ,minimum of 2 tests required, 6 weeks apart & should be positive each time showing persistent positivity to confirm diagnosis of APLA Caution : patients with transient positive tests (due to infection etc) can be diagnosed as positive.

  16. Lupus anticoagulant (LAC) Prolongation of which of these tests is most sensitive for LAC ? A.) Activated partial thromboplastin B.) Dilute Russel Viper venom C.) Kaolin clotting time D.) Partial Thrombin time

  17. Anticardiolipin Antibodies • Were thought to react against cardiolipin but it is now thought to interact with B2GP1 • 85% of APS pts have both LA & aCL • These can be detected using an (ELISA) • Screens for the presence of β2 glycoprotein 1 dependent anticardiolipin antibodies (ACA) • A low platelet count & positivity for antibodies against β2-glycoprotein 1 or phosphatidylserine may also be observed in a positive diagnosis

  18. Anti Beta 2 GP1 • Discovered after LA & ACL • Found without other two in 11% of APS pts & commonly with others. • Binds to B2GP1 disrupting f(x) • B2GP1 has anticoagulant activity through the inhibition of the conversion of prothrombin-thrombin, regulation of protein S, & /or activation of platelets.

  19. Sapporo criteria International Consensus Conference held in Sapporo (’98) Clinical criteria of ( APAS ) Thrombosis, one or more confirmed episodes of venous, arterial, or small vessels disease ‘ Coexisting inherited or acquired thrombotic risk factors are not reasons for excluding patients from a diagnosis of APS trials.’

  20. Sapporo Criteria (updated) Pregnancy criteria : • One or more unexplained fetal deaths > 10 wks of pregnancy • One or more preeclampsia / eclampsia or placental insufficiencies occurring before 34 weeks . • Three or more unexplained consecutive spontaneous abortions < 10 weeks Laboratory criteria • LAC defined by a functional, clot-based assay (ISTH guidelines) • ACL (IgG or IgM) antibody • Anti-b2 glycoprotein I ,IgG or IgM antibody Miyakis, et al., J. Thromb. Haemost.,2006; 4: 295-306.

  21. The International Consensus Statement Definite CAPS diagnosis requires: • Vascular thrombosis in three or more organs or tissues & development of manifestations simultaneously or in < a week & small vessel thrombosis in at least one organ or tissue • Lab. confirmation of presence of aPL • Some serological tests for syphilis may be positive in aPL- positive patients if it is positive) although more specific tests for syphilis that use recombinant antigens are negative • Transient elevations common. Elevations common in autoimmune disease & infections ex. HIV, Hep C, syphilis

  22. Interference with a.)Soluble coagulation factors Protein C/S pathway  inhibition;  fibrinolysis inhibition b.) Coagulation cells: Induction of a pro-adhesive, pro-inflammatory & pro-coagulant endothelial  phenotype ;induction of a procoagulant phenotype in monocytes Interference with : a.) Trophoblast cells: Reduction of proliferation & differentiation; Gonadotrophin secretion impairment Principal pathogenic mechanisms mediated by APL

  23. Pregnancy losses classified as : • Occult (preclinical or chemical) pregnancy loss prior to missed menses. (40% of implantation embryos) • Early pregnancy loss before 12 wk. (13%) • Late pregnancy loss after 12 wk. (1%)

  24. Causes of pregnancy loss Chromosomal 55%of occult & early losses 5% of recurrent losses. Environmental hormonal anatomical Immunological 45% of early losses 95% of late losses

  25. Aneuploidy Aneuploid fetus risk in women > 35yr. age Standard of care is to offer genetic amniocentesis for all pregnant women older than 35 years 1/80 Inherent risk of fetal loss after amniocentesis 1/200

  26. What is Recurrent pregnancy loss ? What actually causes it ?

  27. Definition A recurrent pregnancy loss (RPL) is 3 or more consecutive, spontaneous pregnancy losses, under 20 week gestation from the last menstrual period by the same partner. • Primary recurrent pregnancy loss" refers to couples that have never had a live birth • “Secondary RPL" refers to those who have had repetitive losses following a successful pregnancy

  28. Pregnancy loss in the APLA syndrome - A possible thrombogenic mechanism • Levels of annexin V, a phospholipid-binding protein with potent anticoagulant activity, are markedly reduced on placental villi from women with APLA • APL antibodies reduce the levels of annexin V & accelerate the coagulation of plasma on cultured trophoblasts & endothelial cells. • Reduced annexin V levels on vascular cells may be an important mechanism of thrombosis & pregnancy loss in APLA syndrome. Jacob Rand, Xiao-Xuan Wu, H. Andree, CJ. Lockwood, Seth Guller, J Scher, Peter Harpel, -N Engl J Med ; 337:1630-1631, 1997

  29. Pregnancy loss in autoimmune connective tissue disorders (CTDs) • Adverse outcomes like IUGR, prematurity, recurrent pregnancy loss & stillbirth are common • Systemic lupus erythematosus (SLE) is prototype , others are rheumatoid arthritis, scleroderma, Behcet’s disease & Sjogren’s syndrome • Recent studies show anti-Ro/SSA antibody as a possible factor for unexplained pregnancy loss in SLE. • Antibody is directed against cellular ribonucleoprotein complexes which is present in serum of > 10% pts of CTDs. • It is associated with neonatal lupus & congenital heart block showing passively acquired autoimmunity

  30. How do you proceed ? • Interview the couple together • History of the case is very important • Clinical examination • Investigations as per the history • Reassurance & counselling • Treatment plan : Drugs, maternal & fetal surveillance , dealing with complications • Timely referral to a tertiary centre

  31. Special Investigations • LAC tested by prolonged coagulation time (inhibition of phospholipids) • APTT , KCT , TTIT • Most accurate - Dilute russel viper venom test (DRVVT) • ACL - ELISA - IgG (GPL) IgM (MPL) • IgG/ IgM isotypes of anticardiolipin & antiphosphotidyl serine antibodies • In c/o low titres-repeat after 6-8wks (can revert to normal) • Transient low titres can be found in viral fever • If autoimmune disorders are suspected ANA, anti –nDNA, antiSm, anti-Ro/SSA antibody, anti La (SSP)

  32. General guidelines for anticoagulation in Pregnancy with APS leading to recurrent pregnancy loss So how does one manage the drug treatment in pregnancy ? Very controversial issue !

  33. Commonly used Drugs • Steroids : Reduces ACA, normalises prolongation of invitro coagulation • Complications : ? perinatal outcome preterm labour, preeclampsia • Low dose Aspirin (LDA) : Selective inhibition of Thromboxane A2 No effect on PGI2 • Azathioprine • Warfarin

  34. Which is the commonly used drug for APLA ? A.) Progesterone B.) Folic acid C.) Low dose Aspirin D.) RU- 486

  35. Unfractionated Heparin (UFH) • Potentiates complex formation with AT III + factor VII A  XII A & thrombin • Complications : Reduces platelet bleeding & B.M.D. Low molecular weight Heparin (LMWH) • Once daily dose, less monitoring • Lesser osteopenia, does not cross placenta • Cost factor !!

  36. Trials • Heparin vs Aspirin + prednisolone Live birth 75% Pre-eclampsia, preterm delivery more in latter group • L.S. + LDA Vs Heparin + LDA (n=20) • No placebo • Large multicentric trials needed Cowchock et al .1994

  37. Randomised controlled trial of LDA versus LDA plus heparin in pregnant women with APS • 90 women with APS were randomized into two groups with 1st group receiving 75mg of LDA & 2nd group LDA & Heparin 5000u subcut, every 12 hourly • Outcomes measured were number of live births & miscarriages • LDA group had 19 live births & 26 miscarriages • LDA + heparin group had 32 live births & 13 miscarriages • Significant (p=0.01) improvement in outcomes with heparin R. Rai, H.Cohen et al..,BMJ. (1997 )

  38. Antiphospolipid antibodies Presence of Antiphosholipid antibodies may cause recurrent pregnancy loss • Are antibodies directly responsible ? • Should all women with APA be treated ? • How do you treat a women with positive APLA ?

  39. Controversies surrounding treatment for pregnancy loss • Evidence-based medicine (EBM) has not succeeded in giving patients & physicians the data they need to choose (or not choose) a therapy in the field of pregnancy loss

  40. Women with APLA are advised to take LDA & to start LMWH Rx after pregnancy is diagnosed (80% success) • In case of H/o thrombotic symptoms, Warfarin is used as anticoagulant .Maintain INR between 3.0 - 4.0. • Patients with APLA have minor elevations of PT & are difficult to manage with warfarin. • During pregnancy, LMWH & LDA are preferred to Warfarin (teratogenic effects ) • If previous H/o thrombosis use LMWH in therapeutic doses throughout pregnancy :dose 1mg/kg subcut. • If UFH is used dose is 10,000 u 12 hourly

  41. Since APLA reacts with phospholipids both aPTT & PT can be affected. If UFH used to anticoagulate patients with APLA monitor heparin levels ( 0.35 - 0.70 anti-Xa units 6 hours post injectiont ). • With LMWH , monitoring is easier : predictable dosing & anticoagulant effect . Measure LMW heparin levels in these patients for long term Rx (0.7 - 1.0 anti-Xa units) • Perform prothrombin & proconvertin times ("P&P") to follow anticoagulation. Being less dependent on phospholipids & one can monitor therapy. • If miscarriage occurs with heparin & aspirin & there is a pregnancy again IVIG can be tried (RCT did not show benefit) • In refractory cases plasmapheresis may be used

  42. ACCP Guidelines : Pregnancy & APL - Bates, et al., Chest, 2004; 126: 627S - 644S

  43. Can pregnancy outcome be improved ?

  44. Management of pregnant women • Surveillance depends on past obstetric history • LDA preconception & LDA + LMWH has 80% success rate for treatment of APLA ( Feinberg et al,’ 97 ). • Refer preferably to a tertiary centre with a neonatal backup • Team effort including an obstetrician , hematologist, physician, & neonatologist • Vigilant monitoring • B.P, platelets, complement levels , renal function test (to asses target organ damage )

  45. Care of the fetus • Surveillance depends on past obstetric history • 1st trim U.S.G : viability & dating , nuchal & nasal bone • U.S.G at 19 weeks & serial scans with doppler for early diagnosis of IUGR & waveform abnormalites • Inj Betamethasone 2 doses for enhancing lung maturity • Timely delivery in a centre with a good neonatal backup

  46. Future Possibilities • PAPRE warfarin intensity • PRECLUDE primary prevention • More frequent use of LMWH, IVIG

  47. What to do with the patient with APLA but no thrombotic manifestations ? • Although some of these patients are at risk, especially those with SLE, many will never develop thrombosis • The current recommendation would be to do very careful search for thrombosis. Brain MRI in patients with SLE & in patients with any neurological symptom • If this work-up is negative follow the patient very closely Does immunosuppression work ? APLA seems like an autoimmune disease, but immunosuppression does not prevent recurrent thrombosis, fetal loss, or neurological syndromes & so no role in the Rx of thrombotic APLA

  48. In"catastrophic APLA" plasmapheresis may play a crucial role. • Low intensity anticoagulation with warfarin appears to be mostly effective in APLA (except patients with venous thrombosis) • Many patients will fail low intensity warfarin & need more aggressive anticoagulation. • Heparin anticoagulation appears more effective.Arterial Thrombosis: Warfarin to an INR of 2.0 - 3.0 Venous Thrombosis: Warfarin to an INR of 3.0 - 3.5. Patients who "break through" warfarin should receive heparin.

  49. Inherited Thrombophilia

More Related